Drug-Eluting Stent Dosing Limits Should Be Evaluated In Animals – CDRH
This article was originally published in The Gray Sheet
Executive Summary
Preclinical studies of drug-eluting stents should include overdose testing to ensure the safety of overlapping stents, FDA review staff advises
You may also be interested in...
FDA Joint Reviews Would Benefit From Early Collaboration Meetings – Lewin
FDA should rely increasingly on early collaboration meetings in the review of combination products, according to the fourth in a series of reports prepared by The Lewin Group health care consultant for AdvaMed
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.